Core Viewpoint - Warner Pharmaceuticals (688799.SH) is advancing its "combination of generic and innovative drugs" development strategy by focusing on enhancing its core competitiveness through self-research, collaborative research, and investment incubation [1] Group 1: Strategic Development - The company is implementing a strategy that integrates generic drug development with innovative drug breakthroughs, aligning with industry trends and its own business development strategy [1] - The subsidiary, Qianlie Pharmaceuticals, is focusing on the ophthalmic medication sector, optimizing its product layout, and developing market-potential ophthalmic drugs [1] Group 2: Transaction Details - The company plans to purchase five formulation projects from Qianlie Pharmaceuticals, including Indocyanine Green Injection and Sodium Fluorescein Injection, for a total price of 10.1 million yuan, funded by the company's own resources [1] - The company intends to sell four formulation projects, including Diquafosol Sodium Eye Drops, to Qianlie Pharmaceuticals for a total price of 7 million yuan [1]

Group 1 - The core strategy of the company is to advance the "combination of generic and innovative drugs" by focusing on "intensive consolidation of generics" and "spot breakthroughs in innovative drugs" to enhance its core competitiveness [1] - The subsidiary, Qianlie Pharmaceutical, is focused on the ophthalmic medication sector, continuously optimizing its product layout and developing promising ophthalmic drugs [1] - The company plans to optimize its formulation product pipeline through the integration with Qianlie Pharmaceutical, aligning with its strategic planning and industrial positioning [1] Group 2 - The company intends to purchase five formulation projects from Qianlie Pharmaceutical, including injection products such as Indocyanine Green and Sodium Fluorescein, for a total consideration of 10.1 million yuan, funded by its own resources [1] - The company also plans to sell four formulation projects, including Diquafosol Sodium Eye Drops, to Qianlie Pharmaceutical for a total consideration of 7 million yuan [1]